Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on June 11, 2007
Schizophrenia Bulletin 2007 33(5):1154-1155; doi:10.1093/schbul/sbm068
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
33/5/1154    most recent
sbm068v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Breier, A.
Right arrow Articles by Binneman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breier, A.
Right arrow Articles by Binneman, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Commentary: Wayne Fenton's Impact on Industry

Alan Breier1,2, Larry Alphs3 and Brendon Binneman4
2 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
3 Central Nervous System Clinical Development, Pfizer, Inc
4 Clinical Research and Development, Pfizer

Keywords: schizophrenia / cognition / negative symptoms

The first 10% of the full text of this article appears below.

Wayne Fenton's vision for people with serious mental illnesses was deep and inspiring. He was fiercely committed to improvements in patient care and management so that persons with these disorders could be fully functioning members of society. Fenton was wise enough to recognize that he could not accomplish these goals alone and understood that persistent work with many different stakeholders was necessary. His skill was to bring these diverse groups together so that their wisdom and resources could be pooled in synergistic ways.

A major focus of his vision was the recognition of the substantial unmet medical need related to schizophrenia and the urgent need for novel therapeutics to treat this illness. In order to accomplish this . . . [Full Text of this Article]


   Measurement and Treatment Research to Improve Cognition in Schizophrenia
 

   Treatment Units for Research on Neurocognition and Schizophrenia
 

   Negative Symptoms Project
 

   Wayne Fenton's Legacy
 
1 To whom correspondence should be addressed; tel: 317-277-9222, fax: 317-277-2025, e-mail: a.breier@lilly.com.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?